These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN. Mendonca LO; Malle L; Donovan FX; Chandrasekharappa SC; Montealegre Sanchez GA; Garg M; Tedgard U; Castells M; Saini SS; Dutta S; Goldbach-Mansky R; Suri D; Jesus AA J Clin Immunol; 2017 Jul; 37(5):445-451. PubMed ID: 28503715 [TBL] [Abstract][Full Text] [Related]
3. A novel mutation of interleukin-1 receptor antagonist (IL1RN) in a DIRA patient from Turkey: Diagnosis and treatment. Sözeri B; Gerçeker-Türk B; Yıldız-Atıkan B; Mir S; Berdeli A Turk J Pediatr; 2018; 60(5):588-592. PubMed ID: 30968643 [TBL] [Abstract][Full Text] [Related]
4. A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: description of two unrelated cases from Brazil. Jesus AA; Osman M; Silva CA; Kim PW; Pham TH; Gadina M; Yang B; Bertola DR; Carneiro-Sampaio M; Ferguson PJ; Renshaw BR; Schooley K; Brown M; Al-Dosari A; Al-Alami J; Sims JE; Goldbach-Mansky R; El-Shanti H Arthritis Rheum; 2011 Dec; 63(12):4007-17. PubMed ID: 22127713 [TBL] [Abstract][Full Text] [Related]
5. A case report of a novel compound heterozygous mutation in a Brazilian patient with deficiency of Interleukin-1 receptor antagonist (DIRA). Mendonça LO; Grossi A; Caroli F; de Oliveira RA; Kalil J; Castro FFM; Pontillo A; Ceccherini I; Barros MAMT; Gattorno M Pediatr Rheumatol Online J; 2020 Aug; 18(1):67. PubMed ID: 32819369 [TBL] [Abstract][Full Text] [Related]
6. The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Stenerson M; Dufendach K; Aksentijevich I; Brady J; Austin J; Reed AM Arthritis Rheum; 2011 Dec; 63(12):4018-22. PubMed ID: 21792839 [TBL] [Abstract][Full Text] [Related]
8. Case report: Novel compound heterozygous Urbaneja E; Bonet N; Solis-Moruno M; Mensa-Vilaro A; de Landazuri IO; Tormo M; Lara R; Plaza S; Fabregat V; Yagüe J; Casals F; Arostegui JI Front Immunol; 2024; 15():1381447. PubMed ID: 38646532 [TBL] [Abstract][Full Text] [Related]
9. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. Aksentijevich I; Masters SL; Ferguson PJ; Dancey P; Frenkel J; van Royen-Kerkhoff A; Laxer R; Tedgård U; Cowen EW; Pham TH; Booty M; Estes JD; Sandler NG; Plass N; Stone DL; Turner ML; Hill S; Butman JA; Schneider R; Babyn P; El-Shanti HI; Pope E; Barron K; Bing X; Laurence A; Lee CC; Chapelle D; Clarke GI; Ohson K; Nicholson M; Gadina M; Yang B; Korman BD; Gregersen PK; van Hagen PM; Hak AE; Huizing M; Rahman P; Douek DC; Remmers EF; Kastner DL; Goldbach-Mansky R N Engl J Med; 2009 Jun; 360(23):2426-37. PubMed ID: 19494218 [TBL] [Abstract][Full Text] [Related]
10. Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report. Ulusoy E; Karaca NE; El-Shanti H; Kilicoglu E; Aksu G; Kutukculer N J Med Case Rep; 2015 Jun; 9():145. PubMed ID: 26100510 [TBL] [Abstract][Full Text] [Related]
11. DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name? Cowen EW; Goldbach-Mansky R Arch Dermatol; 2012 Mar; 148(3):381-4. PubMed ID: 22431779 [No Abstract] [Full Text] [Related]
12. Autosomal recessive transmission of TRAPS in a family with a novel TNFRSF1A mutation. Wong KK; Jackson J; Whidborne R; Mallon D; Bennetts B; D'Orsogna LJ Scand J Rheumatol; 2015 May; 44(3):255-6. PubMed ID: 25744939 [No Abstract] [Full Text] [Related]
14. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Grimwood C; Despert V; Jeru I; Hentgen V Rheumatology (Oxford); 2015 Sep; 54(9):1749-51. PubMed ID: 26078218 [No Abstract] [Full Text] [Related]
15. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra. Brau-Javier CN; Gonzales-Chavez J; Toro JR Arch Dermatol; 2012 Mar; 148(3):301-4. PubMed ID: 22431772 [No Abstract] [Full Text] [Related]
16. The IL1RN Mutation Creating the Most-Upstream Premature Stop Codon Is Hypomorphic Because of a Reinitiation of Translation. Moriya K; Kadowaki S; Nakano T; Akarcan SE; Kutukculer N; Aksu G; Sasahara Y; Kure S; Ohnishi H; Casanova JL; Puel A; Fukao T J Clin Immunol; 2020 May; 40(4):643-645. PubMed ID: 32185578 [No Abstract] [Full Text] [Related]
17. Erythematous nodes, urticarial rash and arthralgias in a large pedigree with NLRC4-related autoinflammatory disease, expansion of the phenotype. Volker-Touw CM; de Koning HD; Giltay JC; de Kovel CG; van Kempen TS; Oberndorff KM; Boes ML; van Steensel MA; van Well GT; Blokx WA; Schalkwijk J; Simon A; Frenkel J; van Gijn ME Br J Dermatol; 2017 Jan; 176(1):244-248. PubMed ID: 27203668 [No Abstract] [Full Text] [Related]
18. Mutation screening of the IL-1 receptor antagonist gene in chronic non-bacterial osteomyelitis of childhood and adolescence. Beck C; Girschick HJ; Morbach H; Schwarz T; Yimam T; Frenkel J; van Gijn ME Clin Exp Rheumatol; 2011; 29(6):1040-3. PubMed ID: 22032624 [TBL] [Abstract][Full Text] [Related]
19. New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation. Kuemmerle-Deschner JB; Welzel T; Hoertnagel K; Tsiflikas I; Hospach A; Liu X; Schlipf S; Hansmann S; Samba SD; Griesinger A; Benseler SM; Weber AN Rheumatology (Oxford); 2020 Nov; 59(11):3259-3263. PubMed ID: 32259833 [TBL] [Abstract][Full Text] [Related]